Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of tiragolumab plus atezolizumab, carboplatin, and etoposide in untreated extensive-stage small cell lung cancer
CTR20202178Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tiragolumab in small cell lung cancer (SCLC), sponsored by Roche. Started Dec 2020; status: completed.
02
Drugs
tiragolumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20202178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202178.